NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics logo
$2.05 -0.12 (-5.53%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 11/17/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About MacroGenics Stock (NASDAQ:MGNX)

Advanced

Key Stats

Today's Range
$2.02
▼
$2.18
50-Day Range
$2.05
▼
$4.20
52-Week Range
$1.32
▼
$5.08
Volume
572,902 shs
Average Volume
1.10 million shs
Market Capitalization
$131.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Hold

Company Overview

MacroGenics, Inc. is a biotechnology company focused on discovering and developing antibody-based medicines, primarily for cancer. Founded in 2000 and headquartered in Rockville, Maryland, the company works on its own drug candidates and collaborates with other pharmaceutical and biotechnology companies.

Its research uses antibody-engineering technologies, including platforms designed to engage immune cells against tumors and to deliver therapeutic payloads to cancer cells. MacroGenics’ portfolio has included margetuximab, marketed as Margenza, an antibody treatment approved in the United States for certain patients with HER2-positive metastatic breast cancer.

The company’s development programs and collaborations span multiple regions, with partners involved in advancing or commercializing therapies in international markets. MacroGenics continues to focus on developing antibody-based treatments for cancer.

AI Generated. May Contain Errors.

MacroGenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

MGNX MarketRank™: 
2.5459877366 of 5 stars

MacroGenics scored higher than 51% of companies evaluated by MarketBeat, and ranked 516th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    MacroGenics has a consensus price target of $8.50, representing about 314.6% upside from its current price of $2.05.

  • Amount of Analyst Coverage

    MacroGenics has only been the subject of 2 research reports in the past 90 days.

  • Read more about MacroGenics' stock forecast and price target.
  • Earnings Growth

    Earnings for MacroGenics are expected to decrease in the coming year, from ($1.64) to ($1.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MacroGenics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MacroGenics is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MacroGenics has a P/B Ratio of 5.26. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    8.99% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 3.86, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 2.19%, indicating that investor sentiment is improving.
  • Dividend Yield

    MacroGenics does not currently pay a dividend.

  • Dividend Growth

    MacroGenics does not have a long track record of dividend growth.

  • News Sentiment

    MacroGenics has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for MacroGenics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added MacroGenics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $129,086.00 in company stock.

  • Percentage Held by Insiders

    13.60% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MacroGenics' insider trading history.
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MGNX Stock News Headlines

MacroGenics (NASDAQ:MGNX) Cut to Sell at Wall Street Zen
MacroGenics, Inc. (NASDAQ:MGNX) Stock Now Rated "Hold" by Sell-Side Brokerages
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
MacroGenics (MGNX) Set to Announce Quarterly Earnings on Wednesday
See More Headlines

MGNX Stock Analysis - Frequently Asked Questions

MacroGenics' stock was trading at $1.61 at the beginning of the year. Since then, MGNX shares have increased by 27.3% and is now trading at $2.05.

MacroGenics, Inc. (NASDAQ:MGNX) released its earnings results on Thursday, August, 13th. The biopharmaceutical company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.39. The biopharmaceutical company earned $32.83 million during the quarter, compared to analysts' expectations of $59.14 million. MacroGenics had a negative trailing twelve-month return on equity of 246.62% and a negative net margin of 45.37%.

MacroGenics (MGNX) raised $75 million in an initial public offering on Thursday, October 10th 2013. The company issued 5,000,000 shares at $14.00-$16.00 per share.

MacroGenics' top institutional shareholders include Marshall Wace LLP (2.11%), State Street Corp (1.83%), Pinnacle Associates Ltd. (1.02%) and Goldman Sachs Group Inc. (0.74%). Insiders that own company stock include William K Heiden, Ezio Bonvini and Jeffrey Stuart Peters.
View institutional ownership trends
.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Bristol Myers Squibb (BMY), Alibaba Group (BABA), NVIDIA (NVDA) and TG Therapeutics (TGTX).

Company Calendar

Last Earnings
8/13/2026
Today
11/18/2026
9th Annual Evercore ISI HealthCONx Conference
11/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MGNX
CIK
1125345
Employees
293
Year Founded
2000

Price Target and Rating

High Price Target
$11.00
Low Price Target
$6.00
Potential Upside/Downside
+314.6%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.81)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.62 million
Net Margins
-45.37%
Pretax Margin
-112.87%
Return on Equity
-246.62%
Return on Assets
-31.36%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.75
Quick Ratio
2.75

Sales & Book Value

Annual Sales
$149.50 million
Price / Sales
0.88
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.39 per share
Price / Book
5.26

Miscellaneous

Outstanding Shares
63,910,000
Free Float
55,037,000
Market Cap
$131.02 million
Optionable
Optionable
Beta
1.33

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:MGNX) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners